WEEK2 CASE STUDY ANALYSIS ON ACUTE MYELOID LEUKEMIA
Week 2 Case Study Analysis
Uchenna Patrick Nwaugo
Walden University
NURS 6501N Advanced Pathophysiology
December 8, 2024
This study source was downloaded by 100000898182462 from CourseHero.com on 05-05-2025 22:14:11 GMT -05:00
https://www.coursehero.com/file/246827473/Week-2-Case-Study-Analysis-Nwaugo-Udocx/
, WEEK2 CASE STUDY ANALYSIS ON ACUTE MYELOID LEUKEMIA
Week 2 Case Study Analysis on Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a complex hematologic malignancy characterized by
the uncontrolled proliferation of myeloid progenitor cells (Antar et al.,2020). This disease
predominantly affects older adults but can occur in younger individuals as well. According to
Fleischmann et al (2021), most patients often present with symptoms such as fatigue, bleeding,
and increased susceptibility to infections, which arise due to the disruption of normal blood cell
production by leukemic blasts. The following case study of a 45-year-old male highlights
common clinical features and laboratory findings associated with AML, including the presence
of specific genetic mutations that impact prognosis and treatment strategies. This analysis
explores key aspects such as the cellular abnormalities present in AML, the role of genetic
mutations, and their contributions to clinical symptoms and treatment approaches.
Primary Cell Abnormality in Acute Myeloid Leukemia
The hallmark of AML is the clonal expansion of myeloid progenitor cells that fail to
mature into functional blood cells. This results in the accumulation of immature myeloid cells,
known as leukemic blasts, in the bone marrow and blood. According to the World Health
Organization (WHO), a diagnosis of AML necessitates the presence of at least 20% myeloblasts
in the bone marrow (Nix & Price, 2019). In the presented case, a bone marrow biopsy revealed
hypercellularity with 70% myeloblasts, confirming the diagnosis. Recent advancements in
genomic analysis have identified various subtypes of AML, each associated with distinct genetic
and cytogenetic abnormalities that influence clinical outcomes (Nix & Price, 2019).). Notably,
mutations such as FLT3-ITD are linked to a more aggressive disease course, underscoring the
importance of genetic profiling in AML management.
This study source was downloaded by 100000898182462 from CourseHero.com on 05-05-2025 22:14:11 GMT -05:00
https://www.coursehero.com/file/246827473/Week-2-Case-Study-Analysis-Nwaugo-Udocx/
Week 2 Case Study Analysis
Uchenna Patrick Nwaugo
Walden University
NURS 6501N Advanced Pathophysiology
December 8, 2024
This study source was downloaded by 100000898182462 from CourseHero.com on 05-05-2025 22:14:11 GMT -05:00
https://www.coursehero.com/file/246827473/Week-2-Case-Study-Analysis-Nwaugo-Udocx/
, WEEK2 CASE STUDY ANALYSIS ON ACUTE MYELOID LEUKEMIA
Week 2 Case Study Analysis on Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a complex hematologic malignancy characterized by
the uncontrolled proliferation of myeloid progenitor cells (Antar et al.,2020). This disease
predominantly affects older adults but can occur in younger individuals as well. According to
Fleischmann et al (2021), most patients often present with symptoms such as fatigue, bleeding,
and increased susceptibility to infections, which arise due to the disruption of normal blood cell
production by leukemic blasts. The following case study of a 45-year-old male highlights
common clinical features and laboratory findings associated with AML, including the presence
of specific genetic mutations that impact prognosis and treatment strategies. This analysis
explores key aspects such as the cellular abnormalities present in AML, the role of genetic
mutations, and their contributions to clinical symptoms and treatment approaches.
Primary Cell Abnormality in Acute Myeloid Leukemia
The hallmark of AML is the clonal expansion of myeloid progenitor cells that fail to
mature into functional blood cells. This results in the accumulation of immature myeloid cells,
known as leukemic blasts, in the bone marrow and blood. According to the World Health
Organization (WHO), a diagnosis of AML necessitates the presence of at least 20% myeloblasts
in the bone marrow (Nix & Price, 2019). In the presented case, a bone marrow biopsy revealed
hypercellularity with 70% myeloblasts, confirming the diagnosis. Recent advancements in
genomic analysis have identified various subtypes of AML, each associated with distinct genetic
and cytogenetic abnormalities that influence clinical outcomes (Nix & Price, 2019).). Notably,
mutations such as FLT3-ITD are linked to a more aggressive disease course, underscoring the
importance of genetic profiling in AML management.
This study source was downloaded by 100000898182462 from CourseHero.com on 05-05-2025 22:14:11 GMT -05:00
https://www.coursehero.com/file/246827473/Week-2-Case-Study-Analysis-Nwaugo-Udocx/
